Citigroup Maintains Neutral on Health Catalyst, Lowers Price Target to $2
Citigroup analyst Daniel Grosslight maintains Health Catalyst (NASDAQ: HCAT ) with a Neutral and lowers the price target from $2.5 to $2.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.